Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD-6482
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
AZD-6482 is a potent, selective, and ATP competitive small molecule inhibitor of phosphatidylinositol 3 kinase beta (PI3Kβ). It exhibits high selectivity for PI3Kβ over other class I PI3K isoforms and acts as an antithrombotic agent by inhibiting platelet aggregation without significantly affecting normal hemostasis. The drug was developed primarily for the prevention of thrombosis in conditions such as atherosclerosis that can lead to myocardial infarction or stroke. Its mechanism involves targeting the PI3Kβ pathway in platelets to reduce clot formation. AZD‑6482 has been investigated in clinical trials up to phase II for indications including ischemic stroke and thrombosis[1][7][9].
- Other names
- 2-[[(1R)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoic acid
02
Targets
PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CD (Phosphatidylinositol 3-kinase delta)
Beyond the preview
Go deeper on AZD-6482.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD-6482.